Oncotarget

Research Papers:

Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina

Ziliang Ye, Haili Lu, Qiang Su _, Xinhua Xian and Lang Li

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:92366-92374. https://doi.org/10.18632/oncotarget.21310

Metrics: PDF 1421 views  |   HTML 1698 views  |   ?  


Abstract

Ziliang Ye1,2, Haili Lu2, Qiang Su1, Xinhua Xian2 and Lang Li1

1Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular Institute, Nanning, Guangxi, China

2Guangxi Medical University, Nanning, Guangxi, China

Correspondence to:

Qiang Su, email: [email protected]

Lang Li, email: [email protected]

Keywords: ligustrazine, contrast-induced nephropathy, unstable angina

Received: May 04, 2017    Accepted: August 23, 2017    Published: September 28, 2017

ABSTRACT

Objective: Our purpose was to assess the effect of ligustrazine in the prevention of contrast-induced nephropathy (CIN) in patients with unstable angina (UA).

Methods: 148 patients with UA undergoing coronary angiography and/or percutaneous coronary intervention (PCI) were selected for observation; the patients were divided into a control group (group A, n=74) and a ligustrazine group (group B, n=74). Group A was given routine treatment, while group B was given routine treatment combined with ligustrazine. Serum creatinine (Scr), cystatin C and glomerular filtration rate (eGFR) concentrations were measured before and 1 day, 2 days and 3 days after treatment, and the incidence of contrast-induced nephropathy (CIN) and major cardiovascular events (MACE) were observed in both groups.

Results: The Scr, Cystatin C and eGRF levels in group B were better than in group A after 1 day (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively), 2 days (OR: 3.58, 95% CI: 2.41-4.92; OR: 2.92, 95% CI: 2.83-5.02; OR: 3.28, 95% CI: 3.24-5.14, respectively) and 3 days of treatment (OR: 3.26, 95% CI: 2.17-4.35; OR: 2.85, 95% CI: 2.26-4.02; OR: 3.19, 95% CI: 2.53-4.34, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) of group B were significantly lower than in group A (P<0.05).

Conclusions: Our study suggests that ligustrazine can reduce CIN and MACE in patients with UA when undergoing coronary angiography and/or PCI.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21310